PURPOSE: Melanoma cells can be found in the circulation of patients with melanoma. The following study was conducted to examine whether changes in their presence could provide an early marker of response to therapy. EXPERIMENTAL DESIGN: We measured the presence of several markers of melanoma cells in the peripheral blood of 118 patients with resected stage IIb, III, or IV melanoma before and after immunotherapy with a polyvalent, shed antigen, melanoma vaccine using reverse transcription-PCR assays for tyrosinase, gp100, MART-1, and MAGE-3. Assays were conducted at baseline and after 3, 5, and 11 months of therapy. RESULTS: Overall, 47% of patients were positive for at least one marker during the study. Before vaccine treatment, circulating melanoma cell markers were present in 23% of patients. After 5 and 7 months of vaccine therapy, the proportion of patients with circulating markers decreased by 27% and 55%, respectively (P for trend = 0.02). The recurrence-free survival of patients whose melanoma cell markers disappeared during vaccine treatment was significantly longer than that of patients in whom they increased, i.e., the percentage of patients who were recurrence free at 1 year was 80% versus 58% (P = 0.03). CONCLUSIONS: Therapy with a polyvalent melanoma vaccine was associated with clearance of melanoma cell markers from the circulation, and the clearance was associated with an improved prognosis. These findings suggest that the sequential assay of tumor cells in the circulation by reverse transcription-PCR may provide an early indication of the effectiveness of cancer therapy.
PURPOSE:Melanoma cells can be found in the circulation of patients with melanoma. The following study was conducted to examine whether changes in their presence could provide an early marker of response to therapy. EXPERIMENTAL DESIGN: We measured the presence of several markers of melanoma cells in the peripheral blood of 118 patients with resected stage IIb, III, or IV melanoma before and after immunotherapy with a polyvalent, shed antigen, melanoma vaccine using reverse transcription-PCR assays for tyrosinase, gp100, MART-1, and MAGE-3. Assays were conducted at baseline and after 3, 5, and 11 months of therapy. RESULTS: Overall, 47% of patients were positive for at least one marker during the study. Before vaccine treatment, circulating melanoma cell markers were present in 23% of patients. After 5 and 7 months of vaccine therapy, the proportion of patients with circulating markers decreased by 27% and 55%, respectively (P for trend = 0.02). The recurrence-free survival of patients whose melanoma cell markers disappeared during vaccine treatment was significantly longer than that of patients in whom they increased, i.e., the percentage of patients who were recurrence free at 1 year was 80% versus 58% (P = 0.03). CONCLUSIONS: Therapy with a polyvalent melanoma vaccine was associated with clearance of melanoma cell markers from the circulation, and the clearance was associated with an improved prognosis. These findings suggest that the sequential assay of tumor cells in the circulation by reverse transcription-PCR may provide an early indication of the effectiveness of cancer therapy.
Authors: Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic Journal: Mayo Clin Proc Date: 2011-10 Impact factor: 7.616
Authors: A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman Journal: Br J Dermatol Date: 2012-11-15 Impact factor: 9.302
Authors: Barbara K Zehentner; Heather Secrist; XinQun Zhang; Dawn C Hayes; Richard Ostenson; Gary Goodman; Jiangchun Xu; Mark Kiviat; Nancy Kiviat; David H Persing; Raymond L Houghton Journal: Mol Diagn Ther Date: 2006 Impact factor: 4.074
Authors: Carmen Ruiz; Julia Li; Madelyn S Luttgen; Anand Kolatkar; Jude T Kendall; Edna Flores; Zheng Topp; Wolfram E Samlowski; Edward McClay; Kelly Bethel; Soldano Ferrone; James Hicks; Peter Kuhn Journal: Phys Biol Date: 2015-01-09 Impact factor: 2.583
Authors: Christina L Roland; Merrick I Ross; Carolyn S Hall; Barbara Laubacher; Joshua Upshaw; Amber E Anderson; Anthony Lucci Journal: Melanoma Res Date: 2015-08 Impact factor: 3.599